Olema director granted 29,500 stock options

Olema Pharmaceuticals director Harmon Cyrus received a grant of stock options covering 29,500 shares of common stock.

Rhea-AI Filing Summary

Olema Pharmaceuticals director Harmon Cyrus received a grant of stock options covering 29,500 shares of common stock. The options have an exercise price of $9.51 per share and expire on June 18, 2036. Following this grant, Cyrus holds 29,500 stock options directly.

The options vest in 12 equal monthly installments starting June 18, 2026, conditioned on continued service. Any unvested portion will fully vest on the date of Olema’s next annual meeting of stockholders if not already fully vested, also subject to continued service.

Insider Trade Summary

Grant/Award: 29,500 shares

Grant/Award 1 txn

Insider Harmon Cyrus

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	29,500	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 29,500 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

Options granted: 29,500 options Exercise price: $9.51 per share Expiration date: June 18, 2036 +3 more

6 metrics

Options granted 29,500 options Stock Option (Right to Buy) granted to director Harmon Cyrus

Exercise price $9.51 per share Conversion or exercise price of stock options

Expiration date June 18, 2036 Option expiration for director grant

Underlying shares 29,500 shares Common stock underlying the granted options

Vesting schedule 12 monthly installments Equal monthly vesting starting June 18, 2026, subject to service

Position after grant 29,500 options Total derivative holdings following this transaction

Key Terms

Stock Option (Right to Buy), Common Stock, exercise price, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

exercise price financial

"conversion_or_exercise_price: "9.5100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares subject to the option vest in a series of 12 successive equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"Such shares vest in full on the date of the Issuer's next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Olema Pharmaceuticals (OLMA) director Harmon Cyrus report on this Form 4?

Director Harmon Cyrus reported receiving a grant of stock options for 29,500 shares of Olema Pharmaceuticals common stock. These options are compensation-related, not an open-market trade, and give the right to buy shares at a fixed exercise price of $9.51.

How many Olema Pharmaceuticals (OLMA) options did Harmon Cyrus acquire and at what price?

Harmon Cyrus acquired stock options for 29,500 underlying shares of Olema Pharmaceuticals common stock. The options carry an exercise price of $9.51 per share, meaning he can buy shares at that price if and when the options vest and are exercised.

What is the vesting schedule of Harmon Cyrus’s Olema Pharmaceuticals (OLMA) stock options?

The 29,500 stock options vest in 12 equal monthly installments starting June 18, 2026, subject to Cyrus’s continuous service. Any remaining unvested options will fully vest on the date of Olema’s next annual meeting if not already vested, also requiring continued service.

When do Harmon Cyrus’s Olema Pharmaceuticals (OLMA) options expire?

The stock options granted to Harmon Cyrus expire on June 18, 2036. If the options are not exercised by that expiration date, they lapse. The right to exercise them also depends on the options vesting under the stated service-based schedule.

Is Harmon Cyrus buying or selling Olema Pharmaceuticals (OLMA) shares in this transaction?

This transaction reflects a grant of stock options, not a market purchase or sale of shares. Cyrus acquired derivative securities as compensation, giving him the right to buy Olema common stock in the future at a fixed $9.51 exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 05:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Harmon Cyrus

(Last) (First) (Middle)

C/O OLEMA PHARMACEUTICALS, INC.

780 BRANNAN ST

(Street)

SAN FRANCISCO CALIFORNIA 94103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Olema Pharmaceuticals, Inc. [ OLMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.51	06/18/2026		A		29,500		(1)	06/18/2036	Common Stock	29,500	$0	29,500	D

Explanation of Responses:

1. The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Shawnte Mitchell, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)